MDB Capital Holdings Provides Third Quarter 2024 Update
MDB Capital Holdings (NASDAQ: MDBH) provided its Q3 2024 operational update, highlighting significant achievements including the successful IPO of Invizyne Technologies where MDB retains 48% ownership. The company launched a collaboration with Mayo Clinic for an anti-senescence platform with 67% founding ownership. MDB enhanced its analysis capabilities, screening 8,751 companies and examining 217 potential market leaders. The company expanded its investor base by 15%, increased brokerage accounts by 450+, and grew assets under management from $2M to $28M. PatentVest client engagements increased from three to eight since 2023.
MDB Capital Holdings (NASDAQ: MDBH) ha fornito l'aggiornamento operativo per il terzo trimestre del 2024, evidenziando importanti risultati tra cui il successo dell'IPO di Invizyne Technologies, di cui MDB detiene il 48% delle quote. L'azienda ha avviato una collaborazione con Mayo Clinic per una piattaforma anti-invecchiamento con una partecipazione di fondazione del 67%. MDB ha potenziato le sue capacità di analisi, esaminando 8.751 aziende e analizzando 217 potenziali leader di mercato. L'azienda ha ampliato la sua base di investitori del 15%, ha aumentato i conti di intermediazione di oltre 450 unità e ha fatto crescere le attività in gestione da 2 milioni di dollari a 28 milioni di dollari. Gli impegni dei clienti di PatentVest sono aumentati da tre a otto dal 2023.
MDB Capital Holdings (NASDAQ: MDBH) proporcionó su actualización operacional para el tercer trimestre de 2024, destacando logros significativos, incluyendo la exitosa OPI de Invizyne Technologies, donde MDB mantiene una participación del 48%. La compañía lanzó una colaboración con Mayo Clinic para una plataforma anti-senescencia con un 67% de propiedad fundadora. MDB mejoró sus capacidades de análisis, examinando 8,751 empresas y evaluando a 217 posibles líderes de mercado. La compañía amplió su base de inversores en un 15%, aumentó las cuentas de corretaje en más de 450 y creció los activos bajo gestión de 2 millones a 28 millones de dólares. Los compromisos con clientes de PatentVest aumentaron de tres a ocho desde 2023.
MDB Capital Holdings (NASDAQ: MDBH)는 2024년 3분기 운영 업데이트를 제공하며, Invizyne Technologies의 성공적인 IPO를 포함한 중요한 성과를 강조했습니다. MDB는 48%의 지분을 보유하고 있습니다. 이 회사는 Mayo Clinic과 협력하여 67%의 설립 소유권을 가진 노화 방지 플랫폼을 출시했습니다. MDB는 분석 능력을 향상시키고 8,751개 기업을 스크리닝하며 217개의 잠재적 시장 리더를 조사했습니다. 이 회사는 투자자 기반을 15% 확장하고, 450개 이상의 중개 계좌를 늘리며, 관리 자산을 200만 달러에서 2800만 달러로 증가시켰습니다. PatentVest의 고객 참여는 2023년 이후 3개에서 8개로 증가했습니다.
MDB Capital Holdings (NASDAQ: MDBH) a fourni une mise à jour opérationnelle pour le troisième trimestre 2024, mettant en avant des réalisations significatives, y compris l'IPO réussie de Invizyne Technologies, dont MDB détient 48% des parts. L'entreprise a lancé une collaboration avec Mayo Clinic pour une plateforme anti-sénescence avec une propriété fondatrice de 67%. MDB a amélioré ses capacités d'analyse, en examinant 8 751 entreprises et en analysant 217 leaders potentiels du marché. L'entreprise a élargi sa base d'investisseurs de 15%, augmenté le nombre de comptes de courtage de plus de 450 et fait passer les actifs sous gestion de 2 millions à 28 millions de dollars. Les engagements clients de PatentVest sont passés de trois à huit depuis 2023.
MDB Capital Holdings (NASDAQ: MDBH) hat sein operatives Update für das dritte Quartal 2024 bereitgestellt und dabei bedeutende Erfolge hervorgehoben, darunter den erfolgreichen Börsengang von Invizyne Technologies, an dem MDB 48% Eigentum hält. Das Unternehmen hat eine Zusammenarbeit mit der Mayo Clinic für eine Anti-Seneszenz-Plattform mit 67% Gründungseigentum gestartet. MDB hat seine Analysefähigkeiten verbessert und 8.751 Unternehmen gescreent sowie 217 potenzielle Marktführer untersucht. Das Unternehmen hat seine Investorenbasis um 15% erweitert, die Brokerage-Konten um über 450 erhöht und die verwalteten Vermögenswerte von 2 Millionen auf 28 Millionen Dollar gesteigert. Die Kundenengagements von PatentVest haben sich seit 2023 von drei auf acht erhöht.
- Successful IPO of Invizyne Technologies with 48% ownership retention
- Mayo Clinic collaboration secured with 67% founding ownership stake
- Assets under management grew from $2M to $28M
- 15% increase in shareholder base
- 450+ new brokerage accounts added
- PatentVest client base increased from 3 to 8
- Mayo Clinic collaboration required $150,000 upfront license fee
Insights
This operational update reveals several strategic developments for MDB Capital Holdings. The successful IPO of Invizyne Technologies, where MDB retains a
The expansion to 13 analysts and screening of 8,751 companies shows substantial deal flow capacity. The increase in PatentVest clients from 3 to 8 suggests growing revenue potential in the IP services segment. However, investors should note that detailed financial metrics are pending the upcoming earnings call, making it difficult to assess profitability and cash flow metrics at this stage.
The company's focus on deep technology and biomanufacturing through Invizyne's IPO, combined with the Mayo Clinic anti-senescence platform initiative, positions MDB in high-growth sectors. The PatentVest division's IP intelligence services provide a competitive advantage in identifying and developing technology leaders. Their screening of over 8,700 companies with 217 identified as potential market leaders demonstrates a robust pipeline for future ventures.
The partnership with TCA Venture Group and the development of a specialized clearing and trading platform for public venture investing creates a unique market position. This infrastructure development suggests potential for scaling their business model in the emerging public venture capital space.
Management to Host Conference Call Today at 4:30 p.m. ET
Addison, TX, Nov. 21, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today provides an update on operations through and subsequent to the quarter ended September 30, 2024.
“Throughout the year, we continued to strengthen our operations to increase our capacity to curate and diligence deep technology ideas that we can ultimately finance and help stand up to become leaders in their technology category,” said Christopher Marlett, CEO and Co-Founder of MDB. “At the same time, we deepened and broadened our relationships with our investor community by expanding our self-clearing brokerage offerings and securing new partnerships like we recently announced with one of the largest and most active angel investor networks in the nation, TCA Venture Group.”
Marlett concluded, “On the heels of a successful IPO for Invizyne Technologies, a ‘Big Idea’ company we spun out from the UCLA laboratory to the public market using our complete process, I am happy to report that we have a robust pipeline of new opportunities in the final stages of diligence. As we head into 2025, we are focusing on scaling the number of deep technology ideas we turn into valuable public companies and increasing operational efficiency.”
Third Quarter 2024 and Subsequent Operational Highlights
- Launched and completed an initial public offering for Invizyne Technologies: On November 13, the leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, began trading on NASDAQ under the ticker symbol “IZTC.” MDB co-founded the company and currently owns approximately
48% of outstanding shares. - Announced a collaboration with Mayo Clinic to advance an anti-senescence platform: We launched a new “Big Idea” company through a patent and know-how license agreement with Mayo Clinic to develop a small molecule anti-senescence platform. This collaboration aims to advance research in longevity and age-related disease prevention and involved a
$150,000 upfront license fee to Mayo. Initially, MDB owns a67% founding ownership stake in a new company with the option to invest up to$5 million more for additional equity. - Enhanced our curation and diligence capabilities: We increased the number of trained analysts to thirteen across our organization. Year-to-date, this enabled us to screen 8,751 private and public companies and further examined 217 with the highest probability of becoming market leaders, which has resulted in a robust pipeline of potential “Big Ideas” to bring to market.
- Increased PatentVest engagements: Our integrated IP intelligence, strategy consulting, and IP law firm, which enables visionary companies to develop into technology leaders, worked with eight clients, up from three at the end of 2023. While revenue generation is in its early stages, our initial clients have enabled us to understand how to best position the business for growth and we remain optimistic about the prospects for the company.
- Expanded and deepened relationships with our unique investor community: Since the end of 2023, we increased our shareholder base by
15% , onboarded over 450 new brokerage accounts, increased assets under management from roughly$2 million to$28 million before taking into account the Invizyne IPO, and announced a new partnership with TCA Venture group to continue to expand awareness and participation in the only clearing and trading platform built for public venture investing. - Reported consolidated financial results: On November 12, we filed Form 10-Q with the SEC, which reports consolidated results from all operations, including Invizyne since the IPO did not occur before the quarter end. During today’s investor call, a financial breakout of operations will be discussed. In future quarters, illustrations of separate operating performance will be provided via an “Investor Toolkit” to be used in conjunction with regularly scheduled Form 10-Q filings.
Third Quarter 2024 Results Zoom Webinar at 4:30 p.m. ET Today
Christopher Marlett, CEO and Co-Founder of MDB will lead the call and will be joined by other members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period.
Investors can pre-register now for the Zoom webinar HERE. The live webinar can also be accessed on the day of the event through MDB’s investor relations website at https://investors.mdb.com/.
About MDB Capital Holdings, LLC
Founded in 1997, MDB Capital focuses on launching "Big Ideas" into valuable public companies with a better approach to public venture capital. This approach involves community-driven financings of pre-revenue, early-stage deep technology companies through early public offerings, primarily listed on NASDAQ, as well as post-IPO offerings for already public companies that fit MDB's overall criteria for investment.
MDB Capital is the brand under which MDB Capital Holdings, LLC (NASDAQ: MDBH) and its subsidiaries operate and provide services, which includes a self-clearing broker-dealer and trading platform and an integrated, intellectual property (IP) strategy consulting and law firm. MDB Capital is a registered broker-dealer, Member FINRA/SIPC.
For more information, please visit www.mdb.com.
Forward-Looking Statements
This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond MDB's control. MDB's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in documents that may be filed by MDB from time to time with the SEC. The forward-looking statements included in this press release represent MDB's views as of the date of this press release. MDB anticipates that subsequent events and developments will cause its views to change. MDB undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing MDB's views as of any date subsequent to the date of this press release.
Investor Relations Contact:
IR@mdb.com
Media Contact:
press@mdb.com
FAQ
What was MDBH's ownership stake in Invizyne Technologies after its IPO in Q3 2024?
How much did MDBH's assets under management grow in Q3 2024?
What was the scope of MDBH's company screening activities in Q3 2024?
What is MDBH's ownership stake in the Mayo Clinic anti-senescence platform collaboration?
